This page is intended for folks using HemOnc.org for the first time, although frequent visitors may also learn about new features here. What follows are descriptions of the main features of the wiki.
- 1 Introduction
- 2 Main page
- 3 Disease-specific regimen pages
- 3.1 Table of contents
- 3.2 Guidelines
- 3.3 Regimens
- 3.3.1 Preferred name
- 3.3.2 Regimen alias(es)
- 3.3.3 Example order sets
- 3.3.4 Regimen variants
- 3.3.5 Regimen variant identifiers
- 3.3.6 Trial design
- 3.3.7 Comparator(s)
- 3.3.8 Efficacy
- 3.3.9 Toxicity
- 3.3.10 Entry criteria
- 3.3.11 Disease-modifying drugs
- 3.3.12 Prescription details
- 3.3.13 Supportive medications
- 3.3.14 Dose modifications
- 3.3.15 Treatment duration
- 3.3.16 Multi-part regimens
- 3.3.17 References
- 3.4 Investigational agents
- 3.5 Response criteria
- 3.6 Prognosis
- 3.7 External links
- 4 Drug index
- 5 Individual drug pages
- 6 Search box
- 7 Ontology
HemOnc.org was created in November 2011 as a freely accessible source of chemotherapy drug and regimen information. The site has grown considerably since then. For example, the number of regimens has increased by over 10,000% - from 21 to more than 2200! Here is a general FAQ, with much more detailed information below or on other dedicated pages:
Q: Why did you create this website?
A: The practice of hematology/oncology involves extensive knowledge about numerous drugs and complex treatment regimens. This information is constantly evolving, and when we conducted a needs assessment in 2011, there was no freely available, comprehensive, centralized repository of such information. HemOnc.org was created to address this unmet need. To learn more, please read our Journal of Oncology Practice article as well as this page describing our core philosophy.
Q: Where do you source your information?
A: We look primarily to the published primary literature, including abstracts, and secondarily to sources such as review articles and guidelines. We are also in the process of forming an expert Editorial Board, which will provide additional information for the site. See Sources for more information.
Q: Why don't you have regimen "XYZ"?
A: For chemotherapy regimens, which make up the bulk of HemOnc.org content, we generally require that a regimen be published at least in abstract form before it can be included. We also prefer to only include regimens that have some demonstrated degree of efficacy, and have focused primarily on regimens published in 2005 or later. See Eligibility criteria for more information.
Q: Why don't you have drug "XYZ"?
A: For drugs, we focus first on capturing details on all FDA-approved antineoplastics. We have also tried to include drugs with promising results in clinical trials, preferably those with at least phase II results. Recently, we have also begun to include drugs that are approved in other countries but do not yet have an FDA approval, such as Belotecan (Camptobell).
|back to top|
This is the landing page of HemOnc.org and is primarily a portal to get to the disease-specific regimen pages.
Here, there are quick links to the disease-specific pages, which are organized into four disciplines: 1) solid oncology; 2) malignant hematology; 3) transplant; and 4) classical (a.k.a., benign) hematology. There is also a link to our Editorial Board.
We also have counters here that give you an idea of the scope of the website. The "Regimens" counter is a count of context-specific regimens across all of the pages; the "Regimen variants" counter counts each variant of a context-specific regimen separately, which is why the number is significantly higher. If you are interested in exploring the website through our categories, all pages have at least one categorization and some (such as the medication pages) have many more. The "top-level" categories that you can access directly from the main page are:
- Disease index, with 18 subcategories
- Intervention index, with 3 subcategories
- Regimen index, with 20 subcategories
- General reference pages, with 5 subcategories
Each section is further subdivided into disease-focused groups, driven primarily by the subspecialty organization of hematology/oncology. This also parallels the organization of our Editorial Board.
|back to top|
No matter what page you're on, you'll always see links on the left part of the page which will take you to some of the most useful pages on the site. Clicking the HemOnc.org logo at the top of this sidebar will take you back to the main page.
This section contains the ten most-visited disease-specific pages, as determined by our internal analytics. Clicking here will take you directly to that page.
This menu contains many potentially useful resources, including some our most-visited pages. We have carved out individual pages for some of the most frequently used, such as billing codes, antiemetic support, and performance status. Our vesicant and irritant chemotherapy page is one of our most heavily visited, and might very well be the way you found your way to the site.
Stay in touch
This menu is intended specifically for contributors but given any visitor is a potential contributor, we encourage you to explore the links. In particular, the editing tutorial and the style guide are very helpful to new and active contributors.
This information is not really too useful for casual users of the site but can be relevant to contributors.
Disease-specific regimen pages
|back to top|
These are probably the pages you are going to visit the most. Treatment regimens are grouped into individual pages by cancer histology, hematologic condition, or sometimes by biomarkers, e.g., HER2-positive breast cancer. Although the inclusion of a regimen on a page is not an endorsement of its efficacy, we generally only include regimens that are either current, recommended by well-known guideline organizations (e.g., NCCN, ASCO), or claimed to be efficacious by their author(s). See Eligibility criteria for more information. If you do not see the regimen that you are looking for on the page you think it should be on, it is either:
- Missing and needs to be added to HemOnc.org;
- Intentionally left off the page for not meeting one or more of the criteria just mentioned; or
- Present on an "obsolete" regimens page.
We are still establishing the standards by which a regimen would be considered "obsolete"; please see this page as an example of the work in progress. Proposed definitions of obsolete are:
- No longer recommended by any well-known guideline organization (e.g., NCCN, ASCO);
- More than 10 years from initial publication without any additional updates;
- No longer used in practice (difficult to prove, especially when considering international usage!).
On a particular regimen page, regimens are listed alphabetically under a treatment context; for example the melanoma page has four treatment contexts:
- Adjuvant therapy
- Local therapy
- Metastatic or unresectable disease
- Maintenance immunotherapy for metastatic or unresectable disease
On some pages, the regimens are further organized by whether or not they are described as part of a randomized trial or as a nonrandomized intervention or retrospective analysis.
Our long-term goal is to also organize regimens for advanced or metastatic disease into at least first-line and subsequent lines of therapy, with further subdivisions as driven by the clinical context. For example, the Renal cell carcinoma page has regimens divided into first-line, second-line, and third-line therapy.
Table of contents
|back to top|
Almost every page of HemOnc.org has a table of contents, which allows you to jump quickly to the area of the page that you are most interested in. On various longer pages (e.g., the chemotherapy regimen pages) there are also "back to top" buttons that will bring you back to the table of contents.
|back to top|
Most of the solid tumor pages now contain links to ASCO, ESMO, NCCN, or some specialty-specific guidelines. Hematology pages are still a work in progress, but will focus on ASH, ESMO, NCCN, and some specialty-specific guidelines. Given the sheer number of societies that might issue guidelines, we plan to generally restrict to these better-known sources.
|back to top|
We decide which regimens to include on HemOnc.org based on whether the regimen meets our eligibility criteria. When we use the term "regimen", we are broadly including any prescription with a disease modifying effect, and optionally additional prescriptions to manage the side effects of the disease-modifying agents (i.e., supportive medications). Since we are primarily focused on medical oncology and hematology, the majority of the regimens (or protocols; the words are interchangeable) have one or more antineoplastic or disease-modifying medications; we also have a few regimens that are radiotherapy-based. When describing a regimen, we try to use a consistent style for each chemotherapy regimen, so that you can find the information that you are looking for quickly and easily. Here are the components you will find:
Each regimen has a main description which we have designated as the preferred name. This may not be the most common name used in the published literature or clinical documentation, but this is what we try to capture. A few general notes:
- Single-agent regimens are titled "drug name" monotherapy.
- Two-agent regimens are generically titled "drug A" & "drug B"; the drugs are listed in alphabetical order unless one of the drugs is a monoclonal antibody or a steroid, which are listed last by convention.
- Some two-agent regimens which are widely known by an acronym are listed as such; e.g., AC and Rd.
- Three+ agent regimens are preferentially listed by their widely known acronym.
- Regimens with more than one sequential component are listed as "A, then B".
- We are actively splitting these types of regimens into two separate regimens, "A" and "B".
- Regimens with alternating components are listed as "A/B", e.g., HyperCVAD/MA
For regimens that are known by an acronym, the first thing we do is spell out the acronym. Since these acronyms often contain outdated or brand-names, we include the generic names in parentheses as indicated.
- Example: CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Predniso(lo)ne
If there are alternative acronyms, these are also listed.
Example order sets
Many individual practitioners and organizations do not follow published regimens to the letter. This may be because the published regimen is under-specified, especially with respect to supportive medications, sequencing, and infusion times; or, it may be because local patterns influence treatment choices (again, this is probably most applicable to supportive medications such as antiemetics). For this reason, we have created a number of example order sets, which can be accessed directly or searched for. For example, the mFOLFOX 6 regimen on the colon cancer page has a link to the example orders for mFOLFOX 6 in colon cancer. There are many fewer example order sets than chemotherapy regimens currently, so this is another area where your contributions would be most appreciated!
For most regimens, there is only one variant. However, many regimens have a multitude of variants; e.g., BEAM, used as a preparative regimen for autologous hematopoietic stem cell transplantation, has (at least) 10 variants! Generally we consider a variant to be significantly different dosing, significantly different numbers of cycles, or substitution of a similar but not identical medication (e.g., CHOP with prednisolone substituted for prednisone).
We list each variant of a regimen that we have found, numerically and with a short description. The short description is usually related to the dosing, and sometimes to eponymous variants (e.g., Roswell Park regimen; modified Magrath). For consistency, we are adopting a uniform ordering of variants by increasing dose of the first drug. If two variants have the same dosing but different cycles, we order them by increasing number of cycles. Here is an example of the regimen EC, as used in the adjuvant treatment of breast cancer. As of September 2018, this regimen in this context had six variants:
|Variant||Dose||Number of cycles|
Note that the sixth variant does not have exact dosing instructions. In this case, a range is given for both drugs, and we thus treat it as a separate variant. Sometimes, when a range is given for just one drug of a multi-drug regimen, we will split the regimen into two variants, where one represents the lower bound of the range and one represents the upper bound of the range.
When two fairly similar regimens have been compared head-to-head, with a statistically significant difference, we usually treat these as separate regimens, rather than as variants. A classic example is weekly paclitaxel versus q3wk paclitaxel.
Regimen variant identifiers
For each variant, we reference at least one publication, and more if multiple published protocols have used that variant. In order to frame the appropriate historical context, we try to find the earliest publication of that variant, although this is not always successful. Publications are listed by the last name of the first author "et al." unless in the extremely rare situation that there are only one or two authors. We then list the year of publication as the year that the manuscript was e-published (n.b., this is somewhat different than the standard protocol for bibliographies). If there is a clearly stated protocol acronym or code we list that in parentheses after the year.
Next, we label the type of trial reporting the regimen with a three color code: 1) dark green for RCTs with at least 20 patients assigned to the regimen; 2) light green for RCTs with fewer than 20 patients assigned to the regimen or non-randomized prospective trials with at least 20 patients; 3) light yellow for non-randomized prospective trials with fewer than 20 patients or retrospective studies (of any size). For RCTs, the letter in the parentheses is a short code as follows:
|(Cx)||Control arm when the comparator is a variant of the same regimen|
|(Ex)||Experimental arm when the comparator is a variant of the same regimen|
Note: the vast majority of phase III RCTs have (at least) one control arm and (at least) one experimental arm. In contrast, a substantial minority of randomized phase II RCTs have all experimental arms. Sometimes, it is very difficult to tell from the manuscript which arm is the control and which arm is the experimental - especially with older manuscripts. If we can't determine it from the manuscript, our default is to label all arms as experimental, with two important exceptions:
- Non-active comparators, including placebos, are labeled as a control arm
- If one (or more) arms includes the drugs in the other arm(s) as well as additional drugs (e.g., R-CHOP versus CHOP), the arm with the least drugs is labeled as the control arm.
The exception to both of these rules is for de-escalation trial designs, which can involve an experimental arm with no treatment or with fewer drugs than the control arm. In the future, we will likely modify the coding so that it is clear when a comparator is an escalation versus a de-escalation versus neither (e.g., a chemotherapy versus immunotherapy design).
For RCTs, we provide a clickable link directly to the comparator arm(s), in most cases. There are two exceptions. First, if a comparator is a variant of the same regimen, the link will not be active. Second, some trial designs do not allow for an easy direct link, e.g., arm A patients are treated with "treatment A1", then "treatment A2" and arm B patients are treated with "treatment B". Treatment A1 can't directly be compared to treatment B, in this instance. For such regimens, instead of a direct link to the comparator, you will see a clickable "See link". Clicking on this will take you to the complex multipart regimens page, which have further information about the efficacy of the trial in question.
For almost all phase III trials and most randomized phase II trials, we report the efficacy, as reported in the publication. Much more information is available here. If an interim update reports a change in efficacy, we denote this by a (*) as well as a narrative description just above the regimen details.
For some phase III trials, we report the toxicity, as reported in the original publication or in subsequent publications focused on HRQoL. Much more information is available here.
Most regimens currently on HemOnc.org do not specify the entry (eligibility) criteria. Beginning with the randomized controlled trials, we are beginning to add the "top-line" entry criteria, generally of the format:
This regimen was intended for patients with disease X meeting conditions Y, Z.
This information is taken directly from the manuscript and is not yet in a standardized format. At this point reporting the more detailed inclusion and exclusion criteria is out of scope for the HemOnc.org project. See the Multiple myeloma page for an example of what this new information will look like.
Now, to the actual regimen! We first list the disease-modifying drugs, which for most pages on HemOnc.org, are antineoplastics, alone or in combination. The high-level categories that we use for disease-modifying regimens are:
- Hormonotherapy (aka Endocrine therapy)
Note that with the except of radioimmunotherapy, each of these categories refers to a single modality. In the case of a regimen that combines modalities, e.g., Cisplatin & RT, each modality is described under a separate heading.
Next, we list the disease-modifying drugs in the same order as the regimen acronym, or in the order that they are listed in the absence of an acronym. Each drug is described in a particular format:
Generic_name (Brand_name) x units per unit measure (max dose) route frequency on day(s) y to z (notes)
- Example #1: Doxorubicin (Adriamycin) 50 mg/m2 IV once on day 1
- Example #2: Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 4 & 11
- Example #3: Cyclophosphamide (Cytoxan) 100 mg/m2 PO once per day on days 1 to 14 (with breakfast)
An exception to this rule are continuous infusions, which are described in a slightly different format:
Generic_name (Brand_name) x1 units per unit measure per day IV continuous infusion over y hours, started on day z (total dose per cycle: x2 units per unit measure)
- Example #4: Doxorubicin (Adriamycin) 10 mg/m2/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m2)
- Example #5: Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m2)
- Note that in this example, the continuous infusion is not a multiple of 24 hours, so the "/day" is not used
Generic_name (Brand_name) is always an active link to the drug page. When a primary reference provides details about infusion time, we include them.
- Example #6: Mitoxantrone (Novantrone) 8 mg/m2 IV over 30 minutes once on day 1
When a primary reference provides details about infusion order, we also provide that information.
- Example #7: Mitoxantrone (Novantrone) 8 mg/m2 IV over 30 minutes once on day 1, given second
Immediately after the disease-modifying drugs, we provide information on supportive medications such as antihistamines, antiemetics, growth factors, etc. as provided in the original reference. On occasion the supportive medication is the regimen, e.g., growth factor regimens for low-risk MDS. Some references provide specific drugs but omit doses or routes and we make note of this. Other references recommend a category of medications and we provide the link to one of our drug category pages, e.g. G-CSF. Supportive medication information is highly variable and sometimes not present in the original reference, in which case it is omitted.
We occasionally include information on dose modifications, especially if they are integral to the regimen (e.g., DA-R-EPOCH), but this has not been a focus of the HemOnc.org project to date. Please consult the original reference if you suspect you are not treating a standard patient (e.g., age > 70 years old, reduced cardiac function, etc.).
As with the drug information, we try to maintain a very consistent style for the length and number of cycles. Here are some common examples:
- 21-day cycle for 6 cycles
- 28-day cycle for 4 to 6 cycles
- 8-week course
- 28-day cycles
- Continued indefinitely
Note that the first three examples are of limited duration, whereas the last two are indefinite. While trials often specify exact stopping rules such as progression of disease, clinical practice is more flexible. Generally, disease progression, intolerance due to side effects, or a patient's request to stop therapy for any reason are the main drivers of therapy discontinuation. So as to more accurately reflect this flexibility in clinical practice, we have moved away from specifying the exact stopping rules that might be specified in a trial.
Cycles versus courses
If a treatment is intended to be given more than once, we use the term cycle. If the treatment is intended to be given once (but could still be repeated, such as with certain AML induction regimens), we use the term course.
If a reference reports on a multi-part regimen, we take one of two approaches (this is in flux, see below). If the regimen is clearly of limited duration and meant to be given as a "package" we include all of the information in one place. Here are two examples:
- AC, then T for the adjuvant treatment of breast cancer
- R-Hyper-CVAD alternating with R-MTX-Ara-C in the upfront treatment of mantle cell lymphoma
In other situations, there are clear separations between the phases of treatment. For example, the AIDA 2000 regimen to treat acute promyelocytic leukemia has an induction phase, a three-part consolidation phase, and a maintenance phase. These are all linked together but are kept separate on the regimen page. There are often criteria to move from one part to another part of a multiphase regimen like AIDA 2000, such as achieving a certain level of disease response. When these criteria are reported in the original publication, we include them as a note in italics.
Note: we are moving towards breaking apart all sequential regimens into "modules" linked by a Preceding treatment heading. For example, the first part of "AC, then T (Taxol)" for breast cancer has been merged with AC, and the second part with paclitaxel monotherapy.
Finally, we include all of the original references, in chronological order, that we have used to populate the regimen information. These are listed in PubMed style, and include links to the original article (which is often not free to access), the free PubMed Central article (if available), and the PubMed citation. Many references also include one of the following annotations:
- contains verified protocol: a contributor has reviewed the original article for accuracy of content
- contains protocol: a contributor was able to review the paper or the abstract, but it lacked critical details such as dosing, total number of cycles, etc.
- does not contain protocol: a contributor has reviewed the original article and determined that it does NOT contain the protocol
- contains protocol in supplement: a contributor has reviewed the original article and determined that the protocol is available, but not in the body of the manuscript; when possible, links to the supplement are also provided
If none of these statements are present, please be aware that the information present may not be wholly accurate or complete. Of course, the standard disclaimer always applies!
Updates and subgroup analyses
When a trial has updated results and/or a subsequent subgroup analysis, we nest the reference(s) underneath the original reference. Example:
- BIG 1-98: Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; BIG. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ]. link to original article PubMed
- Update: Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2. link to original article PubMed
- Subgroup analysis: Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20. link to original article PubMed
- Subgroup analysis: Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20;26(12):1972-9. Epub 2008 Mar 10. link to original article PubMed
- Update: Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20;361(8):766-76. link to original article link to PMC article PubMed
- Update: Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-8. link to original article link to PMC article PubMed
- Update: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2019 Jan 10;37(2):105-114. Epub 2018 Nov 26. link to original article link to PMC article PubMed
We occasionally add regimens based on abstract presentations, before a manuscript has been published. In these cases we clearly label the reference with Abstract:. Additionally, once (if) a manuscript is published we replace the abstract reference with the published reference. If you are curious, we do preserve these abstract references as hidden fields; you will need editing privileges in order to view these.
Some of the pages, such as multiple myeloma, have a section where we list some of the drugs with very promising published results in that particular disease. Historically, most of these drugs go on to receive FDA approval, although as always this is not a guarantee!
Many diseases on HemOnc.org have specific response criteria, such as the IMWG international uniform response criteria for multiple myeloma]. For these pages, we have a section on response criteria; we also have a dedicated page describing response to treatment in the categories of strong endpoints (e.g., overall survival, intermediate surrogate endpoints (e.g., time-based endpoints such as progression-free survival), and weak surrogate endpoints (e.g., response-based endpoints such as overall response rate).
As with response criteria, many diseases on HemOnc.org have specific prognostic score or calculators, which we have slowly been adding. For example, the multiple myeloma page has five different prognostic scores.
Some of the disease-specific regimen pages have additional links to external sites that we think are useful. You can also find a large number of external links here.
|back to top|
Beyond the main page and the disease-specific regimen pages, you may want to visit our drug index page, which is accessible at any time through the top of the left sidebar. This page is pretty self-explanatory but there are a few nuances you may be interested in:
Here, we list drugs alphabetically by their generic name. For all approved drugs, we also include their brand name (if there is more than one brand name we try to choose the most recognizable, with a somewhat US-centric bias). Drugs that are under study are labeled in clinical trials. If a drug has been approved in the current or previous calendar year, we list the details right next to the drug, e.g. FDA Approved 7/3/2014. You will probably notice quickly that there are a fair number of red links, which means that the linked page does not yet exist. Help make it happen by contributing!
Here, we list drugs under a number of different categories. A drug can, of course, be listed under many different categories. For instance, most drugs are categorized by at a minimum their route(s) of delivery, mechanism(s) of action, the diseases for which they are used, and the year in which they were approved. See Individual drug pages for more details.
As the name says, these links are placed here because they have directly relevance to drugs, e.g. the ASCO-ONS Standards for Safe Chemotherapy Administration
Individual drug pages
|back to top|
As with the chemotherapy regimens, we try to use a predictable style across all individual drug pages. They are sectioned as follows:
Here, we provide a description of the mechanism of action (if known), as well as the route(s) of drug delivery and any other important information, such as links to REMS programs. For conciseness and simplicity, HemOnc.org currently focuses on treatment regimens and not information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information. For most antineoplastics, we provide links to the package insert provided by the manufacturer, as well as a locally-hosted backup.
Diseases for which it is used
These are the specific conditions for which some degree of efficacy has been demonstrated. This is NOT the same as saying that the drug is FDA-approved or even on an approved compendium listing; we are merely stating that there is some evidence to support efficacy, as defined by our eligibility criteria. These links will take you to the respective treatment regimen page.
If a drug is still in clinical trials, instead of the "diseases for which it is used" heading, we list preliminary results, if they merit inclusion as defined by our eligibility criteria. For example, the drug afuresertib (GSK2110183) has preliminary data for multiple myeloma. If and when these drugs are approved, we replace this heading and move the regimen references to the appropriate page(s).
Patient drug information
As indicated, these links are meant to be useful for patients.
History of changes in FDA indication
Here we try to include, at a minimum, the initial date of FDA approval for a cancer-related or hematologic indication. When the information is available from the FDA, we also include the specific language regarding the approval; this is quite hard to locate for some of the older drugs. We also do our best to update this list with new indications.
Also known as
Here we provide synonyms, which can be only a few or sometimes hundreds, as is the case for dexamethasone. We try to include the original coded designators here, since these are often used colloquially for many years after a drug is approved (e.g. "CPT-11" is still in the vernacular). If you notice that a coded name or other synonym seems to be missing, this is an easy and impactful area for you to contribute to.
At the bottom of each drug page, there is a list of any number of categories that the drug has been assigned to. By clicking on one of these categories, you can easily move from a drug page to a list of similar drugs in the class, or a list of drugs approved in the same year, etc. These categories also parallel the drugs by category on the main drug index page.
|back to top|
There is a search box in the upper right hand corner of every page. If you are looking for something on the site, a good way to start is by typing in some search terms and either pressing enter on your keyboard or clicking the magnifying glass. If there is a page which exactly matches what you've typed in, that will automatically show up, and you can go directly to that page by clicking on the name.
|back to top|
If you've gotten this far in the tutorial, congratulations! You're almost done. In the summer of 2017, we began the process of converting portions of the HemOnc.org website content into a formal ontology, along with some additional external information such as RxNorm identifiers. If you are interested in learning more, including getting access to a beta version of the ontology, please email [email protected].